Other formats:
BibTeX
LaTeX
RIS
@proceedings{1371779,
author = {Aswad, Mohamed Hussam and Kissová, Jarmila and Říhová, Lucie and Zavřelová, J. and Ovesná, Petra and Penka, Miroslav},
booktitle = {XXIII. kongres České internistické společnosti ČLS J. E. Purkyně, Brno},
keywords = {thrombotic events},
language = {eng},
title = {Circulating microparticles as predictor of thrombotic events in BCR/ABL negative myeloproliferative disorders},
year = {2016}
}
TY - CONF
ID - 1371779
AU - Aswad, Mohamed Hussam - Kissová, Jarmila - Říhová, Lucie - Zavřelová, J. - Ovesná, Petra - Penka, Miroslav
PY - 2016
TI - Circulating microparticles as predictor of thrombotic events in BCR/ABL negative myeloproliferative disorders
KW - thrombotic events
N2 - The clinical course of BCR/ABL negative myeloproliferative disorders (MPNs) is frequently complicated by thrombotic events. Microparticles (MPs) are membrane fragments with diameter of 0.1 to 1 microm, which are released by most cell types during their activation or apoptosis. The level of microparticles is known to be elevated in thromboembolic diseases and malignancies. Objective: The aim of this work is to describe the contribution of platelet MPs level and their procoagulant activity to the occurrence of thrombotic complication in patients with BCR/ABL negative MPNs. Methods: The cohort of 121 patients with MPNs (73 males, 48 females) includes 76 patients with essential thrombocythemia, 25 polycythemia vera and 20 primary myelofibrosis. In this cohort was analysed the level of platelet MPs by using flowcytometry and procoagulation activity of MPs by using functional assay (Zymuphen MP-activity kit, Hyphen BioMed). The normal range was confirmed by examination of healthy individuals. Results: The level of platelet MPs was statistically significantly higher in patients with MPNs as compared with healthy individuals (p<0.001); the significancy was confirmed also for procoagulant activity of MPs (p<0.001). Evaluation of patients with history of thrombosis shown no statistically differences in comparison with patients without thrombosis; procoagulant activity of MPs was close to statistical significancy for patients with venous thrombosis (mean 13.7 nM; 95%CI 4.4-42.6 nM vs. 10.7; 95% CI 3.6-31.7 nM; p=0.095). JAK2V617F mutated patients have the higher level of platelet MPs (p=0.047), this correlation was not proven for procoagulant activity of MPs. The level of platelet MPs in patients with polycythemia vera was higher than other types of MPNs (p=0.002). Conclusion: The results of MPs examination might demonstrate the persistent prothrombotic state in patient with MPNs. The clinical utility of MP examination as marker of an increased risk of thrombosis has not been determined yet. The futher studies are needed.
ER -
ASWAD, Mohamed Hussam, Jarmila KISSOVÁ, Lucie ŘÍHOVÁ, J. ZAVŘELOVÁ, Petra OVESNÁ and Miroslav PENKA. Circulating microparticles as predictor of thrombotic events in BCR/ABL negative myeloproliferative disorders. In \textit{XXIII. kongres České internistické společnosti ČLS J. E. Purkyně, Brno}. 2016.
|
